ckd and semaglutide FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes chronic kidney disease compared to placebo. Investigators FLOW Study Highlights: How Semaglutide

Diabetic Ketoacidosis (DKA) DKA is a medical emergency

The good news: most people dont need a heroic fix

September 29, 2024: Increasing Media Coverage Highlights Severe Health Risks Linked to Ozempic Mainstream media have started covering more stories from plaintiffs alleging that the drug Ozempic caused severe gastrointestinal issues, including gastroparesis and intestinal blockage

On tirzepatide, the same principle applies

The dose was subsequently increased to 5 mg without recurrence

When you know what's actually going into your body and how it works, you can have more confidence in your treatment plan and better understand what to expect